Connectivity at Putrajaya Hospital satisfactory, minor network issues in new wing, says Fahmi
However, he noted that concerns were raised regarding connectivity issues in the hospital's newly built wing.
'I took the opportunity to speak with hospital management regarding internet connectivity within the hospital premises. Overall, they expressed satisfaction with both internet and mobile coverage.
'However, they noted some issues in the new wing involving one of the telecommunications service providers,' he told reporters after presenting a contribution under the Kasih@Hawana Fund here today.
He said the provider in question would be asked to assess and optimise its services in the affected area to ensure consistent and reliable coverage for patients, staff and visitors.
Last year, Fahmi said that hospitals were identified as one of the top seven priority areas for improved network coverage.
He said that while some public hospitals have continued to face connectivity challenges, the broader initiative aimed to resolve long-standing in-building mobile coverage issues and support the integration of 5G technology for more advanced medical applications.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malay Mail
an hour ago
- Malay Mail
Hong Kong Men Prioritise Tech Over Health, New Study Reveals
AXA Global Healthcare study highlights worrying gaps in how men prioritise their mental and physical health HONG KONG SAR - Media OutReach Newswire - 22 July 2025 - Men in Hong Kong are significantly more likely to prioritise repairing a device or resolving a banking issue than seeking help for potential signs of serious illness, a new study reveals. The research , commissioned by AXA Global Healthcare, highlights a concerning pattern in how men respond to health issues - particularly when it comes to early action and preventative almost all respondents (95%) said they would fix a broken laptop within a week, only a third (33%) would act as quickly if they noticed potential red flags in their own health - such as unexpected changes in weight, bowel habits or a suspicious symptoms like unusual fatigue (just 27%) and high levels of stress (24%) failed to prompt swift action in many cases, despite being possible early signs of more serious contrast, men in Hong Kong reported far greater urgency when dealing with money, work commitments or vehicles. An overwhelming majority said they'd act urgently if they lost their mobile phone (99%) or bank card (98%), while 96% said they'd prioritise responding to a text or call from their health concerns also took a back seat to pet welfare, with 72% saying they'd respond quickly if their pet seemed comparison, only 64% said they'd see a health professional at all if something felt wrong. Instead, 45% said they'd consult the internet first, and around 10% would turn to AI or a health app for Swatton, Senior Distribution Leader – Asia, at AXA Global Healthcare, said:"It's clear that for many men, computers, money and even work come before their own health. We urgently need to normalise a more proactive approach to wellbeing - not just wait for something to go wrong."The survey of 272 Hong Kong men highlights a critical opportunity to shift behaviour towards more proactive health engagement. While only a minority trust digital health for diagnosis, 31% said they'd feel more confident acting on a health concern if a digital tool flagged it – suggesting potential for wearable devices, trackers, or smart alerts to help bridge the help make healthcare simpler and easier to access, AXA Global Healthcare recently launched a new all-in-one healthcare app that allows members to connect with qualified doctors anytime, by phone or video. Beyond consultations, the app supports users in managing their lifestyle by recording and tracking key physical and mental wellbeing metrics. These wellness trackers deliver insights that enable users to better understand their general health patterns and achieve personalised wellbeing added:"Preventative health shouldn't feel like an afterthought. By tracking physical and mental metrics, users can gain valuable insights that empower them to manage their lifestyle more proactively and work towards their wellbeing goals. Just as you'd regularly check your car or laptop to keep things running smoothly, building habits around your health can lead to better outcomes and greater peace of mind.""For men living or working abroad, this is even more important. Navigating foreign healthcare systems can be confusing and stressful, especially when you're dealing with an unfamiliar language, different medical practices, or insurance rules. Having quick, easy access to trusted healthcare - wherever you are in the world - can make all the difference."Research was carried out online by Obsurvant. All surveys were conducted in May 2025. The samples comprised of 2,083 UK nationals, 512 UAE nationals and 272 Hong Kong nationals. All research conducted adheres to the UK Market Research Society (MRS) code of conduct (2023). Obsurvant is registered with the Information Commissioner's Office and complies with the DPA (2018).Hashtag: #AXA The issuer is solely responsible for the content of this announcement.
Malay Mail
13 hours ago
- Malay Mail
Hospital gave tender to company that failed to deliver cancer treatment machines on time, delaying patients' treatments by months
KUALA LUMPUR, July 21 — A delay in the delivery of critical cancer treatment equipment by a firm has affected patient health care at the Hospital Canselor Tuanku Muhriz (HCTM), revealed the Auditor-General's Report. In an audit report released today, the National Audit Department found that the firm, identified as 0074062-D, failed to provide a linear accelerator (Linac) radiotherapy system as well as a CT-Simulator and Contrast Injector to HCTM on time. The Linac and other supporting equipment were initially scheduled for delivery on September 18, 2024. However, by the time the audit report was concluded on January 17 this year, the Linac machine was yet to be delivered to the said hospital. The report stated that the delay has jeopardised health treatment for at least 20 patients, which was reportedly postponed for up to eight weeks. According to the audit report, the firm failed to supply the equipment on time because the new Linac unit did not meet the technical integration requirements with HCTM's existing system, known as ARIA. 'This technical incompatibility meant that no testing and commissioning work could proceed, further stalling installation and operation,' the report stated. The company then in June last year, asked to postpone the completion of its tender to Feb 12, 2025 due the technical incompatibility, which was approved by HCTM. However, the firm asked for another deferment in December to an unspecified date, which HCTM rejected. Despite the issue, 0074062-D was awarded the contract by the hospital's tender procurement committee. During the tender process, although company 0074062-D met the technical and financial evaluation thresholds, it was not recommended for appointment by the pre-tender committee, technical assessment committee and financial assessment committee. The report stated that the technical assessment committee specifically highlighted that the equipment proposed by the company did not comply with integration requirements for the hospital's existing ARIA system. Despite these concerns, the tender procurement committee proceeded to award the contract to company 0074062-D, overriding the collective recommendations of the evaluation committees. HCTM stated that the tender procurement committee selected company 0074062-D because it fulfilled 90.36 per cent of the technical assessment criteria, submitted the second-lowest bid at RM22 million, and offered the lowest maintenance cost at RM960,000 per year. This was compared to RM1.09 million per year quoted by the lowest bidder in the tender process. However, the National Audit Department found that the explanation unsatisfactory as the report showed the cost saving decision was made despite one company - 0050470-K - submitting a bid for just RM370,000 more than the winning bid, but with the highest score in the technical assessment at 98.05 percent. Apart from the cancer treatment equipment procurement, the Audit Department also raised concerns over two other tenders approved by HCTM — one for catering services and another for lift upgrades. In the catering tender, a RM25.6 million contract was awarded to a company that lacked experience and failed to meet key technical requirements, including having halal certification. Despite not being recommended by the financial assessment committee, the company was chosen due to having sufficient capital. Notably, none of the bidders fully met both technical and financial criteria. Meanwhile, a RM10.8 million contract for lift upgrades was given to company 0726241-U, which had a 'sick project' record — a clear breach of tendering guidelines for major works. Although the hospital claimed that further reviews showed some of the firm's questionable projects were completed on time, the Audit Department maintained that the company should have been disqualified from the start.
Malay Mail
14 hours ago
- Malay Mail
Shanghai Healthcare M&A Fund Strategically Acquires Chengdu Kanghua Biological, Establishing a Fully Integrated Ecosystem
Shanghai Healthcare M&A Fund Strategically Acquires Chengdu Kanghua Biological HONG KONG SAR - Media OutReach Newswire - 21 July 2025 - Chengdu Kanghua Biological Products Co., Ltd. (Stock Code: announced that Shanghai Healthcare M&A Fund ("the M&A Fund") intends to acquire the Company through a strategic agreement. Leveraging its substantial resource and financial strength, the M&A Fund plans to support Kanghua Biological's established product portfolio, accelerate sales of its mature products, and develop industry synergies between Shanghai and Chengdu. The goal is to rapidly expand a diversified vaccine pipeline and build an integrated vaccine ecosystem that combines proven commercialized products with best-in-class R&D vaccine industry is an essential pillar of public health with high entry barriers, stringent oversight, and extended development cycles – all factors contributing to its significant growth potential. As a leading domestic vaccine producer, Kanghua Biological's flagship product - human diploid cell rabies vaccine – stands as China's first domestically developed premium vaccine with over a decade of safe application, established market presence and nationwide distribution. The Company also maintains a robust global innovation pipeline, having successfully licensed its recombinant hexavalent norovirus vaccine overseas. This strategic acquisition, focused on critical segments of the vaccine value chain, will strengthen its strategic positioning. The M&A Fund is committed to supporting Kanghua Biological in leveraging its core product line while harnessing the combined strengthens of Shanghai and Chengdu to accelerate the formation of a next-generation vaccine industry acquisition marks a significant step to drive Shanghai and Chengdu biopharmaceutical cooperation. Post-transaction, Kanghua Biological will capitalize on Shanghai's advanced R&D resources and access to top-tier scientific talent and global capital to enhances its industrial capabilities, manufacturing capacity, and market penetration. The M&A Fund will consolidate diverse industrial assets to promote Kanghua Biological's integration with Shanghai's R&D and clinical networks, creating an end-to-end collaborative system that spans from "clinical R&D to commercialization" and accelerates the development of a full industrial value chain."This transaction goes beyond a typical corporate acquisition, it represents a transformative catalyst for industrial upgrading,""This exemplifies the complementary strengths created by resource-empowered consolidation. With deep biopharmaceutical, financial, R&D, and global network expertise, Shanghai Healthcare M&A Fund will create significant synergies with Kanghua Biological's technologies, products, manufacturing, and domestic distribution to have an outsized impact on the sector."Hashtag: #SIICCapital #ChengduKanghuaBiological #ShanghaiHealthcareM&AFund The issuer is solely responsible for the content of this announcement. About Shanghai Healthcare M&A Fund A core component of Shanghai's state-owned capital fund network, Shanghai Healthcare M&A Fund is managed by SIIC Capital, a subsidiary of SIIC Group. The M&A Fund targets Shanghai's biopharmaceutical sector, aligning government policy objectives with industrial needs by fostering collaboration with leading industry companies, strengthening sector clusters, and enabling asset restructuring. Through capital infusion, improving governance, optimizing management, and executing M&A, the M&A Fund backs "anchor" companies to build complementary and reinforcing links in the value chain, driving the ongoing transformation of specialized subsectors. About Chengdu Kanghua Biological Products Co., Ltd. Chengdu Kanghua Biological Products Co., Ltd. is a biopharmaceutical company engaged in research, manufacture and commercialization of biological products. Established in 2004, the company operates an in-house testing center and GMP-certified bacterial and viral vaccine production facilities. Its marketed portfolio includes the ACYW135 meningococcal polysaccharide vaccine and a freeze-dried human diploid cell rabies vaccine. Kanghua holds GMP certification from China's National Medical Products Administration, has participated in numerous scientific research projects and has been granted patents for over 100 technologies.
